T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

Inclusion Criteria:

* History of histologically confirmed nonmelanoma skin cancer
* Renal transplant recipient ≥ 4 years ago

  * Currently receiving standard multi-agent pharmacologic immunosuppression
* Fitzpatrick skin type I, II, or III
* Sun-damaged skin with ≥ 10 lesions consistent with actinic keratoses OR wart on the upper extremities (arms, forearms, hands), neck, face, and exposed scalp combined
* No history of keloid formation
* No known photosensitivity disorder
* No history of malignant melanoma
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No diagnosis of acute allograft rejection within the past 30 days requiring an increase in immunosuppression
* No invasive malignancy within the past 4 years except curatively excised NMSC, cured polyclonal posttransplantation lymphoproliferative disease, carcinoma in situ of the cervix, stage 0 chronic lymphocytic leukemia, unless all of the following criteria are met:

  * No current evidence of disease
  * No treatment for the invasive malignancy within the past 6 months
  * No concurrent or planned therapy for the invasive malignancy
  * Has an expected disease-free survival of at least 5 years
* No diagnosis of melanoma or melanoma in situ
* No other medical or psychosocial condition that would preclude study participation
* No likelihood, in the opinion of the transplant surgeon/nephrologist, to experience graft loss and/or discontinue standard immunosuppressive therapy during study treatment
* More than 30 days since prior and no concurrent topical chemotherapy (including topical fluorouracil) to areas being studied
* No concurrent topical preparations containing corticosteroids
* More than 30 days since prior and no concurrent local radiotherapy to a study area
* More than 30 days since prior and no concurrent cryotherapy to target lesions
* No prior or concurrent experimental immunosuppressive agents
* More than 30 days since prior investigational medication
* More than 30 days since prior and no concurrent systemic psoralens or retinoids
* More than 60 days since prior and no concurrent laser resurfacing, dermabrasion, or chemical peels to a study area
* No other concurrent investigational agents
* No other concurrent topical medications, including prescription and over the counter preparations, to the areas being studied (e.g., upper arms, forearms, neck, face, and scalp)

  * Concurrent moisturizer, emollient, and sunscreen allowed
* No concurrent topical preparations containing vitamin A derivatives
* No concurrent nonsteroidal anti-inflammatory drugs

  * Concurrent cardioprotective doses of aspirin (\< 100 mg/day) allowed